How New Senior Hires in Industrials Advisory at Lazard (LAZ) May Reshape Its Deal-Making Edge

• Lazard, Inc. recently appointed Bill Young, Jean Greene and Paolo Battaglia as Managing Directors in its Global Industrials Group in New York, with Young leading Diversified Industrials and Greene rejoining after two decades at the firm.
• By adding senior bankers from Bank of America and Goldman Sachs, Lazard is reinforcing its advisory bench across diversified industrials, industrial technology and aerospace & defense.
• We’ll now examine how strengthening Lazard’s Global Industrials leadership with senior hires like Bill Young may influence the existing investment narrative.

We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Lazard Investment Narrative Recap

To own Lazard, you need to believe in its ability to convert advisory talent and a diversified global platform into sustainable earnings growth, while managing the cost of expansion and high debt. The recent appointments in Global Industrials look directionally supportive of the advisory growth story, but they do not materially change the near term tension between investment in senior hires and pressure on net margins, which remains a key risk for the business right now.

Against this backdrop, Lazard’s ongoing share repurchases under its long running buyback plan are the most relevant recent development, because they sit alongside rising personnel investment and could influence how much of any future earnings growth ultimately accrues to each share. For investors watching catalysts, the combination of continued capital returns and the build out of higher fee advisory coverage in sectors like industrial technology and aerospace & defense frames how improved profitability might eventually show up in per share metrics.

Yet while Lazard is adding seasoned deal makers and returning cash to shareholders, investors should still be aware of how higher compensation and expansion costs could compress margins if...

Read the full narrative on Lazard (it's free!)

Lazard’s narrative projects $4.2 billion revenue and $620.0 million earnings by 2028. This requires 11.3% yearly revenue growth and an earnings increase of about $317.5 million from $302.5 million today.

Uncover how Lazard's forecasts yield a $58.17 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$47 to about US$75.68, highlighting how differently investors view Lazard’s prospects. Against that spread, the recent build out of Global Industrials leadership illustrates why some investors may focus on long term advisory growth while others stay cautious about near term margin pressure and elevated debt, so it is worth comparing several viewpoints before deciding how this fits your portfolio.

Explore 4 other fair value estimates on Lazard - why the stock might be worth 7% less than the current price!

Build Your Own Lazard Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Lazard research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Lazard research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lazard's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com